Скачать или смотреть Ifabotuzumab Exploring the Role of Anti-EphA3 in Cancer Research

https://www.assaygenie.com/anti-epha3...

Target and Rationale:
Ifabotuzumab targets the EphA3 receptor tyrosine kinase, which is highly expressed in tumor vasculature and cancer-associated stromal cells, but minimally expressed in normal adult tissues. This selective expression makes EphA3 an attractive therapeutic target.
Quote: "Unlike many other therapeutic targets, EphA3 is minimally expressed in normal adult tissues, making it an ideal focus for cancer therapies."
EphA3 plays a critical role in tumor progression and angiogenesis.

Mechanism of Action:
Disrupting Tumor-Supportive Interactions: Ifabotuzumab binds to EphA3, disrupting interactions crucial for tumor growth and spread.
Antibody-Dependent Cellular Cytotoxicity (ADCC): Ifabotuzumab recruits immune cells (e.g., NK cells, macrophages) to the tumor site, leading to the destruction of cancer cells and stromal elements through ADCC.
Quote: "Upon binding to EphA3, Ifabotuzumab initiates antibody-dependent cellular cytotoxicity (ADCC), a process that recruits immune cells, such as natural killer (NK) cells and macrophages, to the tumor site."

Inhibiting Angiogenesis: Ifabotuzumab disrupts EphA3 signaling pathways, hindering the formation and maintenance of tumor vasculature, thus starving the tumor of essential resources.

Clinical Applications:
Glioblastoma: Ifabotuzumab is being actively investigated for the treatment of glioblastoma, an aggressive brain tumor, due to its ability to alter the tumor microenvironment, impair vasculature, and target stromal networks.

Solid Tumors: Research is exploring Ifabotuzumab's potential in treating a range of solid tumors, including lung, breast, and prostate cancers, where EphA3 is often overexpressed.
Combination Therapies: Ifabotuzumab shows promise in combination with other cancer treatments like chemotherapy, radiation, or immune checkpoint inhibitors, due to its ability to target the tumor microenvironment.

Research and Development (Biosimilar):
A biosimilar version of Ifabotuzumab is available for research purposes. Biosimilars are designed to be highly similar to the original biologic, offering a cost-effective alternative for preclinical studies.

Quote: "Our Ifabotuzumab biosimilar is a research-use-only product designed to facilitate advancements in understanding EphA3's role in cancer. While not identical to the original antibody, it provides comparable performance for preclinical studies and exploratory research."
The biosimilar is intended for research use only and is not suitable for clinical applications.